Switzerland's Novartis said its U.S. subsidiary struck a plea agreement with U.S. investigators to resolve criminal allegations regarding the company's promotion of the epilepsy drug Trileptal, agreeing to pay a $185 million fine. Report [1]
Links:
[1] http://online.wsj.com/article/SB10001424052748703906204575026963160833710.html